Background: Traditional assessments of operative risk in patients with compromised pulmonary function frequently preclude them from lobectomy, often leading to the consideration of less definitive treatments such as sublobar resections or stereotactic body radiation therapy. Objective: This study evaluates the efficacy and safety of single-port thoracoscopic lobectomy for high-risk patients characterized by a predicted postoperative diffusing capacity for carbon monoxide (DLCO) of 40% or less. Methods: We conducted a retrospective analysis of single-port thoracoscopic lobectomy with a predicted postoperative DLCO of ≤40% at Nepean Hospital's between January 2022 to January 2024 Lobectomy/ Segmentectomy was performed in 100 patients with a predicted DLCO less than or equal to 40% which included active smokers as well .The median age was 62 years,56% (n = 56) were women, and 44% (n = 44) . Single port Thoracoscopic lobectomy was performed in 76% (n = 76) and Segmentectomy in 24% (n = 24). There was no operative mortality. All patients were extubated postoperatively in theatre. All patients had intercostal pain buster for pain relief including pre operative and post operative physiotheraphy assessment . Median length of stay of 3 days. The most frequent complications were cardiovascular (14% [n = 14]) and pulmonary (6% [n = 6]). Two patients were discharged on home oxygen, and four required rehabilitation post discharge. Conclusions: Single port Thoracoscopic Lobectomy can be safely performed in patients considered to be high risk for resection by pulmonary function tests. Less invasive approach with intraoperative pain busters for good postop pain relief made in theatre extubation possible resulting excellent postoperative outcomes